| TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ... Nature 554 (7693), 544-548, 2018 | 3710 | 2018 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 674 | 2017 |
| Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor–positive breast cancer R Jeselsohn, R Yelensky, G Buchwalter, G Frampton, F Meric-Bernstam, ... Clinical cancer research 20 (7), 1757-1767, 2014 | 674 | 2014 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 604 | 2017 |
| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 542 | 2014 |
| RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune … S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ... Clinical Cancer Research 22 (6), 1499-1509, 2016 | 529 | 2016 |
| MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ... Cell metabolism 26 (4), 633-647. e7, 2017 | 506 | 2017 |
| High HSP90 expression is associated with decreased survival in breast cancer E Pick, Y Kluger, JM Giltnane, C Moeder, RL Camp, DL Rimm, HM Kluger Cancer research 67 (7), 2932-2937, 2007 | 438 | 2007 |
| Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer US Asghar, AR Barr, R Cutts, M Beaney, I Babina, D Sampath, J Giltnane, ... Clinical Cancer Research 23 (18), 5561-5572, 2017 | 240 | 2017 |
| Quantitative in situ analysis of β-catenin expression in breast cancer shows decreased expression is associated with poor outcome M Dolled-Filhart, A McCabe, J Giltnane, M Cregger, RL Camp, DL Rimm Cancer research 66 (10), 5487-5494, 2006 | 214 | 2006 |
| Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer JM Giltnane, JM Balko Discovery medicine 17 (95), 275-283, 2014 | 190 | 2014 |
| Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer M Hornburg, M Desbois, S Lu, Y Guan, AA Lo, S Kaufman, A Elrod, ... Cancer Cell 39 (7), 928-944. e6, 2021 | 177 | 2021 |
| Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer NS Patil, BY Nabet, S Müller, H Koeppen, W Zou, J Giltnane, A Au-Yeung, ... Cancer cell 40 (3), 289-300. e4, 2022 | 169 | 2022 |
| Therapeutic ligands antagonize estrogen receptor function by impairing its mobility J Guan, W Zhou, M Hafner, RA Blake, C Chalouni, IP Chen, T De Bruyn, ... Cell 178 (4), 949-963. e18, 2019 | 152 | 2019 |
| Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence JM Balko, LJ Schwarz, N Luo, MV Estrada, JM Giltnane, ... Science translational medicine 8 (334), 334ra53-334ra53, 2016 | 138 | 2016 |
| Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer Z Kos, E Roblin, RS Kim, S Michiels, BD Gallas, W Chen, KK van de Vijver, ... NPJ breast cancer 6 (1), 17, 2020 | 128 | 2020 |
| Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer L Formisano, KM Stauffer, CD Young, NE Bhola, AL Guerrero-Zotano, ... Clinical Cancer Research 23 (20), 6138-6150, 2017 | 125 | 2017 |
| The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer JD Joseph, B Darimont, W Zhou, A Arrazate, A Young, E Ingalla, K Walter, ... Elife 5, e15828, 2016 | 124 | 2016 |
| Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American … CB Moeder, JM Giltnane, M Harigopal, A Molinaro, A Robinson, ... Journal of Clinical Oncology 25 (34), 5418-5425, 2007 | 121 | 2007 |
| Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance JM Giltnane, KE Hutchinson, TP Stricker, L Formisano, CD Young, ... Science translational medicine 9 (402), eaai7993, 2017 | 119 | 2017 |
